biostudies-literatureVoorhees PNCI NIH HHS5039-5050https://www.ebi.ac.uk/biostudies/studies/S-EPMC11465741biostudies-literatureUnknown8(19)<h4>Abstract</h4>Optimal therapy for the growing number of patients with lenalidomide (LEN)-refractory multiple myeloma in their first relapse remains poorly defined. We therefore undertook a randomized phase 2 study to evaluate the efficacy and safety of combining the oral proteasome inhibitor ixazomib (IXA) with pomalidomide (POM) and dexamethasone (DEX) in this patient population. The overall response rate (ORR) for POM-DEX was 43.6%, and for IXA-POM-DEX, it was 63.2%. The depth of response, measured by the attainment of at least a very good partial response, favored triplet therapy over doublet therapy (28.9% vs 5.1%; P = .0063). A preplanned interim analysis after 75% of the progression events had occurred demonstrated an improvement in progression-free survival (PFS) that favored IXABlood advancesAlliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.PMC11465741U10 CA180882UG1 CA233180UG1 CA233290UG1 CA233191P30 CA008748U10 CA180821UG1 CA233331UG1 CA233373Voorhees PEfebera YLaubach JMcCarthy PBova-Solem MSuman VRichardson PGRodriguez CTuchman SUsmani SRaje NCarlisle DfalseAlliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.<h4>Abstract</h4>Optimal therapy for the growing number of patients with lenalidomide (LEN)-refractory multiple myeloma in their first relapse remains poorly defined. We therefore undertook a randomized phase 2 study to evaluate the efficacy and safety of combining the oral proteasome inhibitor ixazomib (IXA) with pomalidomide (POM) and dexamethasone (DEX) in this patient population. The overall response rate (ORR) for POM-DEX was 43.6%, and for IXA-POM-DEX, it was 63.2%. The depth of response, measured by the attainment of at least a very good partial response, favored triplet therapy over doublet therapy (28.9% vs 5.1%; P = .0063). A preplanned interim analysis after 75% of the progression events had occurred demonstrated an improvement in progression-free survival (PFS) that favored IXA2024-01-01T00:00:00Z2024 Oct2026-06-01T07:06:38.438Z2025-04-04T23:50:50.718ZS-EPMC114657413905895410.1182/bloodadvances.2024013623